PTGXProtagonist Therapeutics, Inc
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics with a Buy and raises the price target from $170 to $221. ...
- AccessWire
Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
MIMRYLO™ Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to ProtagonistComprehensive Phase 2b Program with PN-881, an Oral ...
- AccessWire
Protagonist Therapeutics to Participate in Four Investment Bank Conferences in November 2026
NEWARK, CA / ACCESS Newswire / October 27, 2026 / Protagonist Therapeutics today announced that senior management will participate in four investment bank ...
- Analyst Upgrades
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics with a Buy and raises the price target from $155 to $160. ...
- PR Newswire
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
NEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare ...
- Analyst Upgrades
UBS Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $184
UBS analyst Alice Nettleton initiates coverage on Protagonist Therapeutics with a Buy rating and announces Price Target of $184. ...
- Analyst Upgrades
Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics with a Outperform rating and raises Price Target to $190. ...
- AccessWire
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
NEWARK, CA / ACCESS Newswire / September 8, 2026 / Protagonist Therapeutics, Inc. today announced that its Board of Directors has authorized a share repurchase program under which the Company may ...
- AccessWire
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026
NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics today announced that Dinesh V. Patel, Ph.D., President and Chief Executive ...
- Analyst Upgrades
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $180
Barclays analyst Etzer Darout maintains Protagonist Therapeutics with a Overweight and raises the price target from $153 to $180. ...
- Analyst Upgrades
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $190
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics with a Outperform and raises the price target from $178 to $190. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics with a Buy and raises the price target from $167 to $170. ...
- AccessWire
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
MIMRYLO™ is the First and Only Hepcidin Mimetic Peptide Therapy Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera, Offering a Novel Mechanism to Maintain Hematocrit Control, Meaningfully ...
- AccessWire
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the ...
- Analyst Upgrades
BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $178
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics with a Outperform and raises the price target from $112 to $178. ...
- Analyst Upgrades
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $170
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics with a Buy and raises the price target from $145 to $170. ...
- Analyst Upgrades
Wedbush Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $173
Wedbush analyst Yun Zhong maintains Protagonist Therapeutics with a Outperform and raises the price target from $118 to $173. ...
- Analyst Upgrades
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks. ...
- Analyst Upgrades
Goldman Sachs Upgrades Protagonist Therapeutics to Buy, Raises Price Target to $186
Goldman Sachs analyst Richard Law upgrades Protagonist Therapeutics from Neutral to Buy and raises the price target from $110 to $186. ...
- Analyst Upgrades
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $153
Barclays analyst Etzer Darout maintains Protagonist Therapeutics with a Overweight and raises the price target from $151 to $153. ...
- AccessWire
Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early AdoptionRusfertide NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026Comprehensive Phase 2b Program with PN-881, an Oral IL-17 ...
- AccessWire
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / August 4, 2026 / Protagonist Therapeutics, Inc. today reported that on July 31, 2026, it granted inducement awards to two recently hired employees in accordance with the ...
- AccessWire
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / July 16, 2026 / Protagonist Therapeutics, Inc. today reported that on July 15, 2026, it granted inducement awards to three recently hired employees in accordance with the ...
- Analyst Upgrades
Barclays Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $151
Barclays analyst Etzer Darout maintains Protagonist Therapeutics with a Overweight and raises the price target from $119 to $151. ...
- Analyst Upgrades
Truist Securities Maintains Buy on Protagonist Therapeutics, Raises Price Target to $145
Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics with a Buy and raises the price target from $121 to $145. ...